Département d'Anatomie et de Cytologie Pathologiques, Pôle de Biologie et de Pathologie, CHU A. Michallon, and Université Joseph Fourier, INSERM U823, Institut Albert Bonniot, Grenoble, France
Service d'Anatomie Pathologique, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Eur Respir J. 2015 Jul;46(1):207-18. doi: 10.1183/09031936.00119914. Epub 2015 Apr 30.
Anaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma result in kinase activity targetable by crizotinib. Although fluorescence in situ hybridisation (FISH) is the reference diagnostic technique, immunohistochemistry (IHC) could be useful for pre-screening. Diagnostic yields of ALK IHC, FISH and quantitative reverse transcriptase PCR performed in 14 French pathology/molecular genetics platforms were compared. 547 lung adenocarcinoma specimens were analysed using 5A4 and D5F3 antibodies, two break-apart FISH probes and TaqMan kits. Clinicopathological data were recorded. 140 tumours were ALK rearranged (FISH with ≥15% of rearranged cells) and 400 were ALK FISH negative (<15%). FISH was not interpretable for seven cases. ALK patients were young (p=0.003), mostly females (p=0.007) and light/nonsmokers (p<0.0001). 13 cases were IHC negative but FISH ≥15%, including six cases with FISH between 15% and 20%; eight were IHC positive with FISH between 10% and 14%. Sensitivity and specificity for 5A4 and D5F3 were 87% and 92%, and 89% and 76%, respectively. False-negative IHC, observed in 2.4% of cases, dropped to 1.3% for FISH >20%. Variants were undetected in 36% of ALK tumours. Discordances predominated with FISH ranging from 10% to 20% of rearranged cells and were centre dependent. IHC remains a reliable pre-screening method for ALK rearrangement detection.
间变性淋巴瘤激酶 (ALK) 基因重排在肺腺癌中导致可被克唑替尼靶向的激酶活性。虽然荧光原位杂交 (FISH) 是参考诊断技术,但免疫组织化学 (IHC) 可能有助于预筛选。比较了 14 个法国病理学/分子遗传学平台进行的 ALK IHC、FISH 和定量逆转录聚合酶链反应的诊断效果。使用 5A4 和 D5F3 抗体、两个分离 FISH 探针和 TaqMan 试剂盒分析了 547 例肺腺癌标本。记录了临床病理数据。140 个肿瘤存在 ALK 重排(FISH 中≥15%的重排细胞),400 个肿瘤为 ALK FISH 阴性(<15%)。7 例 FISH 结果不可解释。ALK 患者年轻(p=0.003),多为女性(p=0.007)和轻烟/非吸烟者(p<0.0001)。13 例 IHC 阴性但 FISH≥15%,包括 6 例 FISH 在 15%至 20%之间;8 例 IHC 阳性,FISH 在 10%至 14%之间。5A4 和 D5F3 的敏感性和特异性分别为 87%和 92%,89%和 76%。2.4%的病例出现假阴性 IHC,FISH>20%时降至 1.3%。在 36%的 ALK 肿瘤中未检测到变体。FISH 范围在 10%至 20%的重排细胞之间的差异占主导地位,且与中心有关。IHC 仍然是 ALK 重排检测的可靠预筛选方法。